Radius Health To Get Third Day-180 List Of Outstanding Issues
Zacks Investment Research | Dec 18, 2017 05:45AM ET
Radius Health, Inc. (NASDAQ:RDUS) announced that the Committee for Medicinal Products for Human Use (CHMP) will provide a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC.
The CHMP informed the company that it will refer the marketing authorisation application (MAA) to a scientific advisory group for additional advice as part of its ongoing risk-benefit assessment.
Hence, the CHMP expects to issue an opinion on the same during the first half of 2018.
In July 2017, the CHMP issued a second Day-180 List of Outstanding Issues and requested additional data analyses related to the safety and efficacy of abaloparatide-SC for their ongoing regulatory review.
The delay in approval in Europe is disappointing given the potential market.
Radius Health’s share price has decreased 21.8% in the year so far compared with the industry’s gain of 7.4%.
We note that Tymlos (abaloparatide) was approved by the FDA in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Although the osteoporosis market in the United Sates has great potential as approximately 1.4 million postmenopausal women experience an osteoporotic fractur each year, Tymlos is expected to face significant competition from Eli Lilly & Co's (NYSE:LLY) Forteo and Amgen Inc's (NASDAQ:AMGN) Prolia.
Moreover, the approved label carries a boxed warning of osteosarcoma (a malignant bone tumor).
Meanwhile, Radius Health is also developing abaloparatide-TD for as a short wear-time transdermal patch. In December 2015, the company initiated a human replicative clinical evaluation to compare the optimized abaloparatide-TD patch with its subcutaneous formulation. The company posted positive results from the trial in September 2016.
The company is currently focused on completing the manufacturing, scale up, and other required activities needed to initiate a pivotal study to evaluate bioequivalence to abaloparatide-SC. The transdermal patch program has the potential to allow physicians who treat osteoporosis, but rarely use injectable drugs, to expand their practices to include the use of anabolic therapy.
Zacks Rank & Key Pick
Get The News You Want
Radius Health currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the healthcare sector is Corcept Therapeutics Inc. (NASDAQ:CORT) which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks (Strong Buy) here .
Corcept’s earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The company’s stock is up 124.5% so far this year.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.